表紙
市場調査レポート

Lucentis(糖尿病の細小血管合併症)- 予測と市場分析

Lucentis (Macular Edema and Macular Degeneration) - Forecast and Market Analysis to 2023

発行 GlobalData 商品コード 294515
出版日 ページ情報 英文 86 Pages
即納可能
価格
本日の銀行送金レート: 1USD=106.71円で換算しております。
Back to Top
Lucentis(糖尿病の細小血管合併症)- 予測と市場分析 Lucentis (Macular Edema and Macular Degeneration) - Forecast and Market Analysis to 2023
出版日: 2014年10月31日 ページ情報: 英文 86 Pages
概要

糖尿病の細小血管合併症(糖尿病性腎症・網膜症・神経障害)の市場全体は、主要7ヶ国(米国、欧州5ヶ国、日本)において極めて高いレベルのアンメットニーズに直面しています。莫大な可能性にもかかわらず、過疎のパイプラインで世界的な障壁に直面しています。糖尿病性網膜症の市場では、新しい抗VEGF(血管内皮増殖因子)療法の急速な取り込みが進み、力強い成長を示しています。その一方で、糖尿病性腎症・神経障害の市場では、ジェネリックの競合企業の数が増加しています。

当レポートでは、免疫グロブリンG1(lgG1)モノクローナル抗体(mAb)を遺伝子組換えによりヒト化したFab断片である、Lucentisによる治療法について調査分析し、疾病の概要と治療ガイドライン、競合情勢、製品情報、主要国の売上予測などを提供して、概略以下の構成でお届けいたします。

第1章 目次

第2章 イントロダクション

第3章 疾病の概要

  • 病因・病態生理
    • 糖尿病性腎症
    • 糖尿病性網膜症
    • 糖尿病性神経障害
  • 予後
  • QOL
  • 症状

第4章 疾病の管理

  • 治療の概要
    • 診断と照会
    • スクリーニング
    • 治療ガイドライン

第5章 競合評価

  • 概要
  • 戦略的競合企業の評価

第6章 Lucentis(ranibizumab)

  • 概要
  • 効能
  • 安全性
  • SWOT分析
  • 予測

第7章 付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GDHC480DFR

Macular Edema is a condition where fluid accumulates on the macula, leading to vision impairment or in severe cases even vision loss. The three main types of ME are diabetic macular edema (DME), and macular edema following either a central or branch retinal vein occlusion (ME-CRVO and ME-BRVO). Age-related macular degeneration (AMD) is a painless eye condition which leads to gradual, irreversible, loss of central vision, and is one of the leading causes of blindness among people aged 50 and over in the developed world. Currently the ME and AMD markets are dominated by the use of anti-VEGF monotherapy, however, in recent years, corticosteroid implants have been reaching the ME market which could challenge the stronghold these drugs have in this sector. The AMD market will see the arrival of the first therapies to treat dry AMD, fulfilling a huge unmet need in the management of this retinal disease, and these first-in-class therapies will strongly drive the market growth over the next ten years. The launch of wet AMD adjunctive therapies will also see a significant change in the treatment of AMD patients and have a positive impact on the market growth.

Lucentis (ranibizumab) is an anti-VEGF-A monoclonal antibody (mAb) fragment developed by Genentech/Roche. It is derived from the larger parent molecule, bevacizumab, which is another anti-VEGF drug marketed as Avastin by Genentech/Roche/Chugai. It was hoped that Lucentis, as a lower-molecular-weight, humanized fragment of an immunoglobulin G1 (IgG1) mAb, would result in improved retinal penetration over Avastin, and therefore, confer superior efficacy.

Scope

  • Overview of Macular Edema and Macular Degeneration, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Lucentis including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Lucentis for the top seven countries from 2013 to 2023.
  • Sales information covered for the US, France, Germany, Italy, Spain, the UK and Japan

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return.
  • Stay ahead of the competition by understanding the changing competitive landscape for Macular Edema and Macular Degeneration.
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential.
  • Make more informed business decisions from insightful and in-depth analysis of Lucentis performance.
  • Obtain sales forecast for Lucentis from 2013-2023 in top seven countries (the US, France, Germany, Italy, Spain, the UK and Japan).

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Related Reports

3. Disease Overview

  • 3.1. Macular Degeneration Overview
    • 3.1.1. Etiology and Pathophysiology
    • 3.1.2. Classification
    • 3.1.3. Symptoms and Diagnosis
  • 3.2. Macular Edema Overview
    • 3.2.1. Etiology and Pathophysiology
    • 3.2.2. Classification
    • 3.2.3. Symptoms and Diagnosis

4. Disease Management

  • 4.1. Diagnosis and Treatment Overview
    • 4.1.1. Macular Edema Diagnosis
    • 4.1.2. Macular Degeneration Diagnosis
    • 4.1.3. Treatment Guidelines and Leading Prescribed Drugs
    • 4.1.4. Clinical Practice

5. Competitive Assessment

  • 5.1. Overview

6. Lucentis (ranibizumab)

  • 6.1. Overview
  • 6.2. Efficacy - Macular Degeneration
  • 6.3. Efficacy - Macular Edema
  • 6.4. Safety

6.5. SWOT Analysis

  • 6.6. Forecast

7. Appendix

  • 7.1. Bibliography
  • 7.2. Abbreviations
  • 7.3. Methodology
  • 7.4. Forecasting Methodology
    • 7.4.1. Diagnosed ME and AMD Patients
    • 7.4.2. Percentage of Drug-Treated Patients
    • 7.4.3. General Pricing Assumptions
    • 7.4.4. Individual Drug Assumptions
  • 7.5. Primary Research - KOLs Interviewed for this Report
  • 7.6. Primary Research - High-Prescribers Survey
  • 7.7. About the Authors
    • 7.7.1. Analyst
    • 7.7.2. Therapy Area Director
    • 7.7.3. Global Head of Healthcare
  • 7.8. About GlobalData
  • 7.9. Disclaimer

List of Tables

  • Table 1: ARM System Classification of AMD
  • Table 2: Symptoms of AMD
  • Table 3: National and International Treatment Guidelines for ME and AMD
  • Table 4: Most Prescribed Drugs for ME and AMD in the Global Markets, 2013
  • Table 5: Leading Treatments for ME and AMD, 2014
  • Table 6: Product Profile - Lucentis
  • Table 7: Lucentis SWOT Analysis, 2014
  • Table 8: Global Sales Forecast ($m) for Lucentis, 2013-2023
  • Table 9: Surveyed High-Prescribing Physicians (Non-KOLs), by Country

List of Figures

  • Figure 1: Anatomy of the Eye and Macula
  • Figure 2: Amsler Grid viewed by Patient with Normal Vision and with wAMD
  • Figure 3: Color Fundus Photographs of Dry and Wet AMD
  • Figure 4: FAF Imaging of GA
  • Figure 5: Imaging of wAMD
  • Figure 6: CMT in DME
  • Figure 7: RVOs (BRVO and CRVO) on an FA
  • Figure 8: Increased CRT in ME-RVO
  • Figure 9: ME Clinical Treatment Flowchart
  • Figure 10: AMD Clinical Treatment Flowchart
Back to Top